Krackhardt Florian, Kherad Behrouz, Krisper Maximilian, Pieske Burkert, Laule Michael, Tschöpe Carsten
Department of Cardiology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany, Germany.
Cardiol J. 2017;24(3):250-258. doi: 10.5603/CJ.a2017.0024. Epub 2017 Mar 1.
Conduction disturbances requiring permanent pacemaker implantation following transcatheter aortic valve replacement (TAVR) are a common problem. Pacemaker implantation rates after TAVR appear to be higher compared to conventional aortic valve replacement. The aim of this study was to analyze whether a high annulus implantation conveys the benefit of a decreased rate of permanent pacemaker implantation while being safe and successful according to Valve Academic Research Consortium 2 (VARC2)-criteria.
A total of 23 patients with symptomatic severe aortic valve stenosis, an aortic annulus of 19-27 mm and at high risk for surgery were treated with the Lotus valve. In all patients the valve was implanted in a high annulus position via femoral access. The primary device performance endpoint was VARC2-defined device success after 30 days and the primary safety endpoint was the need for permanent pacemaker implantation.
The mean age was 73.23 ± 7.65 years, 46% were female, 38% were New York Heart Association class III/IV at baseline. Thirty-day follow-up data were available for all patients. The VARC2-defined device success rate after 30 days was 22/23 (96%). 2/21 (10%) patients required a newly implanted pacemaker due to 3rd degree atrioventricular block. 25% of the patients developed a new left bundle branch block after valvuloplasty or device implantation. 21 of the 23 patients (96%) had no other signs of conduction disturbances after 30 days.
The approach of the modified implantation technique of Lotus TAVR device was safe and effective. The incidence of need for a permanent pacemaker following TAVR could be significantly reduced due to adopted implantation protocol.
经导管主动脉瓣置换术(TAVR)后需要植入永久性起搏器的传导障碍是一个常见问题。与传统主动脉瓣置换术相比,TAVR后的起搏器植入率似乎更高。本研究的目的是分析高位瓣环植入是否能在符合瓣膜学术研究联盟2(VARC2)标准的情况下,带来降低永久性起搏器植入率的益处,同时确保安全且成功。
共有23例有症状的严重主动脉瓣狭窄、主动脉瓣环直径为19 - 27mm且手术风险高的患者接受了Lotus瓣膜治疗。所有患者均通过股动脉途径将瓣膜植入高位瓣环位置。主要器械性能终点是30天后VARC2定义的器械成功,主要安全终点是是否需要植入永久性起搏器。
平均年龄为73.23±7.65岁,46%为女性,38%在基线时为纽约心脏协会III/IV级。所有患者均有30天的随访数据。30天后VARC2定义的器械成功率为22/23(96%)。2/21(10%)的患者因三度房室传导阻滞需要新植入起搏器。25%的患者在瓣膜成形术或器械植入后出现新的左束支传导阻滞。23例患者中有21例(96%)在30天后没有其他传导障碍的迹象。
Lotus TAVR器械改良植入技术的方法是安全有效的。由于采用了植入方案,TAVR后需要永久性起搏器的发生率可显著降低。